DDInter856 DDInter1731
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Sunitinib {u} (Compound) resembles {v} (Compound) Metoclopramide
Sunitinib {u} (Compound) treats {v} (Disease) pancreatic cancer
Sunitinib {u} (Compound) binds {v} (Gene) SBK1
Sunitinib {u} (Compound) upregulates {v} (Gene) CRIP1
Sunitinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Sunitinib {u} (Compound) downregulates {v} (Gene) INTS3
Sunitinib {u} (Compound) causes {v} (Side Effect) Candida infection
Sunitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Sunitinib (Compound) resembles Metoclopramide (Compound)
Sunitinib (Compound) treats pancreatic cancer (Disease)
Sunitinib (Compound) binds SBK1 (Gene)
Sunitinib (Compound) upregulates CRIP1 (Gene)
Sunitinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Sunitinib (Compound) downregulates INTS3 (Gene)
Sunitinib (Compound) causes Candida infection (Side Effect)
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline